Background/Aims: The aim was to describe the factors determining total pubertal growth (TPG) in adolescents with growth hormone deficiency (GHD), Turner syndrome (TS), who were small for gestational age (SGA) or had idiopathic short stature (ISS). Methods: The patients were documented within KIGS (Pfizer International Growth Database). TPG was defined as growth from puberty onset – spontaneous (>B1 or testes >3 ml) or induced with sex steroids to adult height in idiopathic GHD (n = 639; males 399), TS (n = 463), SGA (n = 59; males 35), and ISS (n = 130; males 87). Algorithms to predict TPG at puberty onset were developed by multiple linear regression analysis. Results: In GHD (males, females) and TS TPG could be explained with the same four predictors: (1) age (years) at puberty onset (neg.), (2) age – bone age at puberty onset (pos.), (3) height – midparental height (SDS) at puberty onset (neg.), and (4) mean dose of growth hormone (GH) during puberty (pos.). The algorithms explained 66, 65 and 68%, respectively, of the variability with total errors of 4.5, 3.8 and 2.9 cm, in spontaneous and induced TPG. Conclusions: TPG is determined by the same factors at puberty onset in adolescents with GHD, TS, SGA or ISS treated with GH. Thus, TPG depends mostly on the outcomes achieved at the end of prepubertal growth and less so on the dose of GH.

1.
Rose SR, Municchi G, Barnes KM, Kamp GA, Uriarte MM, Ross JL, Cassorla F, Cutler GB Jr: Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991;73:428–435.
2.
Ghigo E, Arvat E, Gianotti L, Lanfranco F, Broglio F, Aimaretti G, Maccario M, Camanni F: Hypothalamic growth hormone-insulin-like growth factor-I axis across the human life span. J Pediatr Endocrinol Metab 2000;13(suppl 6):1493–1502.
3.
Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J: High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech Cooperative Study Group. J Clin Endocrinol Metab 2000;85:3653–3660.
4.
Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO: The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 2003;88:4748–4753.
5.
Declaration of Helsinki: Recommendations guiding doctors in clinical research. Adopted by the World Medical Association in 1964. Wis Med J 1967;66:25–26.
6.
Ranke MB: The Kabi Pharmacia International Growth Study: aetiology classification list with comments. Acta Paediatr Scand 1991;379:87–92.
7.
Ranke MB, Lindberg A: Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009;19:1–11.
8.
Price DA, Jönsson P: Induction of puberty with sex steroids: a description of clinical practice recorded in KIGS. Pharmacia & Upjohn International Growth Database. Biannu Rep 1996;2:14.
9.
Lindberg A, Ranke MB: Data analyses within KIGS; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics – 20 Years of KIGS. Basel, Karger, 2007, pp 23–28.
10.
Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989;52(suppl):1–125.
11.
Ranke MB, Stubbe P, Majewski F, Bierich JR: Spontaneous growth in Turner’s syndrome. Acta Paediatr Scand 1988;343(suppl):22–30.
12.
Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P: An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paediatr Scand 1991;80:756–762.
13.
Greulich W, Pyle S: Radiographic Atlas of the Skeletal Development of the Hand and Wrist. Stanford, Stanford University Press, 1959.
14.
Cook RD, Weisberg S: Residuals and Influence in Regression. New York, Chapman & Hall, 1982.
15.
Weisberg S: Applied Linear Regression. Chichester, Wiley, 1985.
16.
Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
17.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.
18.
Tanner JM, Whitehouse RH, Marubini E, Resele LF: The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol 1976;3:109–126.
19.
Buckler JM, Wild J: Longitudinal study of height and weight at adolescence. Arch Dis Child 1987;62:1224–1232.
20.
Largo RH, Gasser T, Prader A, Stuetzle W, Huber PJ: Analysis of the adolescent growth spurt using smoothing spline functions. Ann Hum Biol 1978;5:421–434.
21.
Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955–1997. Pediatr Res 2000;47:316–323.
22.
Slyper AH: The pubertal timing controversy in the USA, and a review of possible causative factors for the advance in timing of onset of puberty. Clin Endocrinol (Oxf) 2006;65:1–8.
23.
Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G: Spontaneous pubertal development in Turner’s syndrome. J Clin Endocrinol Metab 1997;82:1810–1813.
24.
Bondy CA, Turner Syndrome Study Group: Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007;92:10–25.
25.
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008;18:89–110.
26.
Saenger P, Czernichow P, Hughes I, Reiter EO: Small for gestational age: short stature and beyond. Endocr Rev 2007;28:219–251.
27.
Bourguignon JP: Linear growth as a function of age at onset of puberty and sex steroid dosage: therapeutic implications. Endocr Rev 1988;9:467–488.
28.
Kiess W, Conways G, Ritzen M, et al: Induction of puberty in the hypogonadal girls – practices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002;57:66–71.
29.
Drobac S, Rubin K, Rogol AD, Rosenfield RL: A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab 2006;19:55–64.
30.
Price DA, Shalet SM, Clayton PE: Management of idiopathic growth hormone deficient patients during puberty. Acta Paediatr Scand 1988;347(suppl):44–51.
31.
August GP, Julius JR, Blethen SL: Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience. Pediatrics 1998;102:512–516.
32.
Albertsson-Wikland K, Alm F, Aronsson S, Gustafsson J, Hagenas L, Hager A, Ivarsson S, Kriström B, Marcus C, Moell C, Nilsson KO, Ritzén M, Tuvemo T, Westgern U, Westphal O, Aman J: Effect of growth hormone (GH) during puberty in GH deficient children: preliminary results from an ongoing randomized trial with different dose regimes. Acta Paediatr 1999;88(suppl):80–84.
33.
Martin DD, Hauspie RC, Ranke MB: Total pubertal growth and markers of puberty onset in adolescents with GHD: comparison between mathematical growth analysis and pubertal staging methods. Horm Res 2005;63:95–101.
34.
Coelho R, Brook CG, Preece MA, Stanhope RG, Dattani MT, Hindmarsh PC: A randomised study of two doses of biosynthetic human growth hormone on final height of pubertal children with growth hormone deficiency. Horm Res 2008;70:85–88.
35.
Massa G, Vanderschueren-Lodeweyckx M, Malvaux P: Linear growth in patients with Turner syndrome: influence of spontaneous puberty and parental height. Eur J Pediatr 1990;149:246–250.
36.
Massa G, Heinrichs C, Verlinde S, Thomas M, Bourguignon JP, Craen M, François I, Du Caju M, Maes M, De Schepper J, Belgian Study Group for Pediatric Endocrinology: Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J Clin Endocrinol Metab 2003;88:4168–4174.
37.
Soriano-Guillen L, Coste J, Ecosse E, Léger J, Tauber M, Cabrol S, Nicolino M, Brauner R, Chaussain JL, Carel JC: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 2005;90:5197–5204.
38.
Hernández MI, Mericq V: Pubertal development in girls born small for gestational age. J Pediatr Endocrinol Metab 2008;21:201–208.
39.
Lazar L, Pollak U, Kalter-Leibovici O, Pertzelan A, Phillip M: Pubertal course of persistently short children born small for gestational age (SGA) compared with idiopathic short children born appropriate for gestational age (AGA). Eur J Endocrinol 2003;149:425–432.
40.
Vicens-Calvet E, Espadero RM, Carrascosa A, Spanish SGA Collaborative Group: Small for Gestational Age: Longitudinal study of the pubertal growth spurt in children born small for gestational age without postnatal catch-up growth. J Pediatr Endocrinol Metab 2002;15:381–388.
41.
Rosilio M, Carel JC, Ecosse E, Chaussain JL: Adult height of prepubertal short children born small for gestational age treated with GH. Eur J Endocrinol 2005;152:835–843.
42.
Boonstra V, van Pareren Y, Mulder P, Hokken-Koelega A: Puberty in growth hormone-treated children born small for gestational age (SGA). J Clin Endocrinol Metab 2003;88:5753–5758.
43.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM, 2007 ISS Consensus Workshop participants: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210–4217.
44.
Ranke MB: Towards a consensus on the definition of idiopathic short stature. Horm Res 1996;45(suppl 2):64–66.
45.
Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr, Baron J: Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3140–3148.
46.
Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L: Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch Pediatr Adolesc Med 2002;156:230–240.
47.
Rekers-Mombarg LT, Wit JM, Massa GG, Ranke MB, Buckler JM, Butenandt O, Chaussain JL, Frisch H, Leiberman E: Spontaneous growth in idiopathic short stature. European Study Group. Arch Dis Child 1996;75:175–180.
48.
Hindmarsh PC, Brook CG: Final height of short normal children treated with growth hormone. Lancet 1996;348:13–16.
49.
Kawai M, Momoi T, Yorifuji T, Yamanaka C, Sasaki H, Furusho K: Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J Pediatr 1997;130:205–209.
50.
López-Siguero JP, García-Garcia E, Carralero I, Martínez-Aedo MJ: Adult height in children with idiopathic short stature treated with growth hormone. J Pediatr Endocrinol Metab 2000;13:1595–1602.
51.
Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenäs L, Ivarsson SA, Jonsson B, Kriström B, Marcus C, Nilsson KO, Ritzén EM, Tuvemo T, Westphal O, Aman J: Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 2008;93:4342–4350.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.